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Available online 28 December 2015Induced pluripotent stem cells (iPSCs) were generated from skin ﬁbroblasts isolated from a 58-year old male
with a L150P mutation in the presenilin 1 (PSEN-1) gene, which is responsible for the majority of familial cases
of Alzheimer's disease (AD). The iPSCswere established by co-electroporationwith episomal plasmids containing
hOCT4, hSOX2, hL-MYC, hKLF4, hNANOG, hLIN28, and short hairpin RNA against TP53. The iPSCs contained the spe-
ciﬁc heterozygous mutation c.449CNT, had normal karyotype, expressed the expected pluripotency genes and
displayed in vitro differentiation potential to the three germ layers. The iPSCs may be useful for studying familial
AD pathology in vitro.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Resource tableame of stem cell construct H234 C2
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erson who created resource Bjørn Holst, Alisa Tubsuwan
ontact person and email Bjørn Holst, bho@bioneer.dk
ate archived/stock date December 05, 2014
rigin Human skin ﬁbroblasts
ype of resource Biological reagent: induced pluripotent stem
cell (iPS); derived from an Alzheimer patient
carrying PSEN-1 L150P mutationb-type Induced pluripotent stem cells
ey transcription factors hOCT4, hSOX2, hL-MYC, hKLF4, hNANOG,
hLIN28, and shRNA for TP53 (Addgene
plasmids 27,077, 27,078 and 27,080;
Okita et al. 2011)uthentication Identity and purity of cell line conﬁrmed by
integration analysis, sequencing of mutation,
pluripotency analysis, karyotyping and
in vitro differentiation (Fig. 1)nk to related literature (direct
URL links and full references)N/Aformation in public databases N/AIn. This is an open access article under2. Resource details
Skin ﬁbroblasts were collected from a 58-year old male with familial
Alzheimer's disease (AD) caused by a c.449TNC mutation in the PSEN-1
gene and electroporated with episomal plasmids of human OCT4, SOX2,
L-MYC, KLF4, NANOG, LIN28, and shRNA for TP53 using a Neon™ electro-
poration device (Invitrogen). Sequencing analysis of the iPSCs con-
ﬁrmed a heterozygous c.449TNC mutation in PSEN-1, which results in
lysine being substituted by proline (L150P) (Fig. 1A). The absence of
the three reprograming plasmids in the genome was veriﬁed by
quantitative PCR after 10 passages (Fig. 1B). The iPSCs expressed the
pluripotency markers NANOG, OCT4, TDGF1, DNMT3B, GABRB3, and
GDF3 (International Stem Cell Banking Initiative 2009) in the same
range as BION010-A iPSC, a control iPSC line described previously
(Rasmussen et al. 2014; Fig. 1C). Expression of thepluripotencymarkers,
NANOG, OCT4, SSEA4, and TRA-1-60 at the protein level was conﬁrmed
by immunoﬂuorescence staining (Fig. 1D). In vitro differentiation
followed by ICC analysis with the ectodermal marker beta-III-Tubulin
(TUJ1), themesodermalmarker smoothmuscle actin (SMA) and the en-
dodermal marker alpha-feto protein (AFP) demonstrated the differenti-
ation potential into cells representing all three germ layers (Fig. 1E). In
addition, the iPSCs presented a normal karyotype (46, XY) (Fig. 1F).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Characterization of iPSCs generated from an Alzheimer's disease patient with L150P mutation in the PSEN-1 gene. (A) Sequencing results of mutation in iPSCs conﬁrmed a
heterozygous c.449TNC mutation in PSEN-1. *Marks the mutation site. (B) Quantitative PCR for reprograming plasmids in H234 C2 iPSC, ﬁbroblasts, and positive control. Data is shown
as the fold change (2-ΔΔCt) with ﬁbroblasts and GAPDH as internal controls. (C) Quantitative PCR analysis of pluripotency-associated genes in H234 C2 iPSC and BION010-A iPSC. Data
is shown as the fold change (2-ΔΔCt) with ﬁbroblasts and GAPDH as internal controls. (D) Immunoﬂuorescence staining for the pluripotency markers OCT4 (red), TRA-1-60 (green),
NANOG (red) and SSEA4 (green). Scale bar correspond to 100 μm. (E) In vitro differentiation potential into the three germ layers demonstrated by ICC analyses of adhered EBs using
TUJ1 (ectodermmarker; green), SMA (mesodermmarker; green) and AFP (endodermmarker; red). Scale bar correspond to 50 μm. (F) Representative karyotype of H234 C2 iPSC (46, XY).
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The studywas approved by the regional scientiﬁc ethical committee
in the Capital Region of Denmark (RH), (protocol number H-4-2011-
157), Copenhagen, Denmark and written informed consent was
obtained in all cases.
3.1. Cell culture and reprogramming
Skin ﬁbroblasts from a 58-year old male were obtained from a skin
biopsy and cultured in DMEM (Life Technologies) supplemented with
10% fetal bovine serum (FBS, Life Technologies), 1% Glutamine (Life
Technologies) and 2 ng/ml of ﬁbroblast growth factor 2 (FGF2). Fibro-
blasts (1 × 105) were electroporated with 1 μg of three episomal
plasmids containing gene sequences for hOCT4, hSOX2, hKLF4, hL-MYC,
hLIN-28 and short hairpin RNA for TP53 (shP53) (Addgene), using a
Neon™ device (Invitrogen) as previously described (Okita et al. 2011).
After electroporation, cells were cultured on ESC grade Matrigel (BD
Biosciences) in mTeSR1 medium (Stem Cell Technologies, Vancouver,
BC, Canada). After four weeks, individual iPSC colonies were manually
picked and transferred to Matrigel-coated dishes in mTeSR1 medium.
The iPSC lines were routinely passaged using 0.5 mM EDTA (Sigma)
and frozen in liquid nitrogen in mTeSR1 containing 10% DMSO and
thawed in the presence of 10 μM of Rho-kinase inhibitor (Y-27632,
Sigma).
3.2. Sequencing analysis
Genotyping of the PSEN-1mutation was performed by PCR ampliﬁ-
cation of the PSEN-1 gene using a primer pair covering the mutation in
exon 5 (Table 1). PCR was performed using Taq DNA polymerase(Takara) according to the manufacturer's instructions. Amplicons
were sequenced and electropherograms were analyzed with an ABI
PRISM310 Genetic Analyzer.
3.3. Analysis of reprogramming plasmid integration
Genomic DNA was isolated from parental ﬁbroblasts, iPSCs, and ﬁ-
broblasts electroporated with episomal plasmids as a positive control
using DNeasy Blood and Tissue Kit (Qiagen). Quantitative PCR was car-
ried out using primers speciﬁc to the episomal plasmids (Okita et al.
2011). The data was analyzed using the 2-ΔΔCt method relative to ﬁbro-
blasts and GAPDH was used as an internal control.
3.4. Quantitative PCR analysis of pluripotency markers
Total RNA was puriﬁed from iPSCs, ﬁbroblasts and the iPSC line
BIONi010-A (Rasmussen et al. 2014) using RNeasy Mini Kit (Qiagen)
and converted to cDNA using High-Capacity cDNA Reverse Transcrip-
tion Kit (Thermo Scientiﬁc) according to the manufacturer's instruc-
tions. qPCR analysis was performed using TaqMan probes obtained
from Applied Biosystems (Table 1) according to the manufacturer's in-
structions. qPCR assays were carried out in duplicate or triplicate with
the StepOnePlus™ system (Thermo Scientiﬁc). The relative fold-
changes in expression were calculated using the 2-ΔΔCt method relative
to GAPDHwith ﬁbroblasts as a reference (set to 1).
3.5. In vitro differentiation by embryoid body (EB) formation
Embryoid body (EB) formation was performed by transferring
Dispase-treated clumps of iPSCs onto ultra-low attachment plates
(Corning, Corning, NY, USA) in mTeSR1. After 2 days of culture, the
Table 1
Primers and TaqMan probes used for sequencing and qRT-PCR.
Assays Amplicons Sequence (5′ to 3′) or TaqMan
gene expression assay number
Modiﬁcation
Sequencing
analysis
PSEN-1
gene
GTGAGTTGGGGAAAAGTGAC –
TCCACAGTGAGGAGGAAGAA –
Pluripotency
analysis
TDGF1 HS02339497_g1 5′Fam3′NFQ-MGB
GABRB3 HS00241459_m1 5′Fam3′NFQ-MGB
NANOG HS02387400_g1 5′Fam3′NFQ-MGB
GDF3 HS00220998_m1 5′Fam3′NFQ-MGB
OCT4 HS0999632_g1 5′Fam3′NFQ-MGB
DNMT3B HS00171876_m1 5′Fam3′NFQ-MGB
GAPDH Hs03929097_g1 5′Fam3′NFQ-MGB
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replacement (Life Technologies, Carlsbad, CA, USA), 1× nonessential
amino acid, 2 mM L-glutamine, 0.1 mM 2-mercaptoethanol and 1%
pen/strep. After 7 days, the EBs were plated on 0.1% gelatin-coated
culture dishes and cultured in DMEM supplemented with 10% FBS,
2 mM L-gultamine and 1% pen/strep for up to three weeks. The cells
were ﬁxed for 15 min in 4% paraformaldehyde (PFA) for ICC analysis
with the antibodies TUJI, SMA and AFP.
3.6. Immunoﬂuorescence staining
Cells grown on cover slips were ﬁxed at room temperature with 4%
PFA in PBS for 10 min and then permeabilized with 0.1% Triton X-100
in PBS for 15 min. Non-speciﬁc binding was blocked with 1% BSA for
30 min. The cells were then incubated with primary antibodies
overnight at 4 °C. To assess the expression of pluripotent markers, im-
munoﬂuorescence staining was performed with primary antibodies
against OCT4 (1:500, 09–0023, Stemgent), NANOG (1:1000, 500-P236,
Peprotech), SSEA4 (1:400, 330302, BioLegend), TRA-1-60 (1:400,
330602, BioLegend). In addition, primary antibodies against β-III
tubulin (TUJ1; 1:3000, T8660, Sigma Aldrich), smooth muscle actin
(SMA;1:1000, M0851, DAKO), and α-fetoprotein (AFP;1:1000, A0008,
DAKO) were used to conﬁrm the differentiation potential of H234 iPSC
into all three germ layers. After three PBS washes, the cells were incu-
bated with ﬂuorescence-conjugated secondary antibodies (AlexaFluor
488: goat anti-mouse, and Cyanine 3: goat anti-rabbit) for 60 min, andmounted on glass slides with mounting medium containing DAPI (Life
technologies).
3.7. Karyotype analysis
iPSCs and ﬁbroblasts were treated for 45 min with KaryoMAX
colcemid (Life Technologies) and karyotyping was performed on
G-banded metaphase chromosomes using standard cytogenetic
procedures.
4. Veriﬁcation and authentication
Karyotyping was performed at the Cell Guidance Systems, England.
At least 10metaphases were analyzed per sample with an approximate
resolution of 550 to 600 bands per haploid genome. The results showed
a normal 46, XY karyotype, free of any discernible abnormalities
(Fig. 1F). iPSC line identity and purity were furthermore conﬁrmed by
sequencing of the PSEN-1 gene (Fig. 1A) and ICC with pluripotency
markers (Fig. 1C).
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